MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
LYON, France, May 12, 2025--(BUSINESS WIRE)--Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced additional findings following full data readout for the exploratory single-arm, open-label Phase 1b clinical trial named IASO (NCT05889572) evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS).
In November 2024, the Company announced that the trial had met its primary endpoint assessing the safety and tolerability of MaaT033 with multiple doses, following the independent Data Safety and Monitoring Board (DSMB) conclusion. As a reminder, the exploratory Phase 1b trial enrolled a total of 15 participants across two centers in France Hôpital de la Pitié-Salpêtrière – AP-HP and the University Hospital of Lille. An external Scientific Advisory Committee took place at the end of March 2025 to review the full data. Below are the key takeaways from the Committee's review:
MaaT033 demonstrated a favorable safety and tolerability profile, supported by biomarker and microbiome analyses.
A rapid and sustained engraftment of bacterial species from MaaT033 was observed, mostly occurring within the first month and maintained during the 1-month follow-up period.
A slower rate of disease progression (based on ALSFRS-R slopes) was noted to be interpreted with caution given the short follow up, limited sample size and single-arm Phase 1b design. The ALSFRS-R is a standard functional scale in ALS trials to track the progression of the disease. The slope reflects how many points are "lost" (=disease progression) per month. In the final data readout for the IASO trial, the following was observed for the ALSFRS-R Total score slope:
From first symptoms to baseline, the median slope was –0.7 points/month (range: –1.2 to –0.3)
From baseline to Day 84 (D84), the median slope slowed to –0.3 points/month (range: –2.4 to +1.0)
No variation at D84 in the levels of neurofilaments, a marker associated with neuronal injury in ALS.
In addition, the Scientific Advisory Committee provided insights regarding the best population to target in a Phase 2 trial.
"These encouraging findings from the IASO Phase 1b trial confirm the favorable safety and tolerability profile of MaaT033 in ALS patients. They also highlight the therapeutic potential of microbiome modulation beyond oncology and open new avenues for development in neurodegenerative diseases, as evidence continues to grow around the gut-brain connection," said Gianfranco Pittari, MD, PhD, Chief Medical Officer of MaaT Pharma.
The study was conducted in close collaboration with the French patient association Tous en Selles contre la SLA (TECS), highlighting the essential role of patients and their advocates in advancing science, and with the support of experts from the French academic networks FILSLAN and ACT4ALS-MND.
"Recognizing the significant unmet medical need in ALS and with the will to support those affected, we applied our discovery platform to this new disease area, demonstrating its potential beyond our primary focus in oncology with encouraging Phase 1 data. In light of the Company's strict financial discipline, and considering the recent successes achieved in oncology, we are actively seeking partners with a focus on ALS and the financial capacity to support new options to fight this disease," stated Hervé Affagard, CEO and co-founder of MaaT Pharma.
–--
About MaaT033MaaT033, a standardized, donor-derived, high-richness, high-diversity oral Microbiome Ecosystem TherapyTM containing anti-inflammatory ButycoreTM species, is currently being developed as an adjunctive therapy to improve overall survival in patients receiving HSCT and other cellular therapies. MaaT033 is developed with the "pooling" technology, which allows pooling donations from multiple donors to create a standardized product with high microbial richness and diversity. It aims to ensure optimal microbiota function and to address a larger patient population in a chronic setting. MaaT033 has been granted Orphan Drug Designation by the European Medicines Agency (EMA).
About Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease in the US and Charcot's disease in Europe, is a progressive neurodegenerative disorder affecting motor neurons in the brain and spinal cord. This leads to muscle weakness, loss of voluntary movement, and eventually, paralysis and on an average lead to death in 3 to 5 years. ALS could affect up to 60,000 patients in US and EU by 2040 and has currently no curative treatment and few symptomatic treatments.
About MaaT PharmaMaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Forward-looking StatementsAll statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as "target," "believe," "expect," "aim", "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250511855391/en/
Contacts
MaaT Pharma – Investor RelationsGuilhaume DEBROAS, Ph.D.Head of Investor Relations+33 6 16 48 92 50invest@maat-pharma.com
MaaT Pharma – Media RelationsPauline RICHAUDSenior PR & Corporate Communications Manager+33 6 14 06 45 92media@maat-pharma.com
Rx Communications Group – U.S. Investor Relations Michael MillerManaging Director+1-917-633-6086mmiller@rxir.com
Catalytic Agency – U.S. Media Relations Heather SheaMedia relations for MaaT Pharma +1 617-286-2013 heather.shea@catalyticagency.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
44 minutes ago
- Entrepreneur
Estee Lantos Launches Refined Masterclass to Help People Slow Biological Aging by Transforming Stress from Within
Learn how nervous system regulation and optimised, yet not rigid lifestyle practices such as sleep, nourishment, movement can help you feel your best and slow down ageing, beginning June 1st You're reading Entrepreneur United Kingdom, an international franchise of Entrepreneur Media. Estee Lantos, a respected voice in biohacking and holistic wellness, is proud to unveil the revamped version of her "Biohack with Nervous System-first Masterclass – a transformative experience designed to help participants understand the factors that influence their biological age and how they can respond to life with more ease & connection. The masterclass is available online from June 1st and is priced at just £50. This 90-minute pre-recorded training is a powerful entry point into Estee's broader wellness ecosystem, offering education and practical tools to to help people feel better, function optimally, and maintain youthful vitality. Estee Lantos "Our culture teaches us to manage stress after it happens. But what if you could train your body to respond differently in the first place?" says Estee. "The key to longevity isn't just in what you eat or how you sleep—it lies in a holistic approach that begins with how effectively you can guide your nervous system back to safety, and live from a place of ease. Inside the Masterclass: A Step-by-Step Guide to Real Change Participants will learn: The science of stress and how the nervous system responds How to create safety within the body through cues and awareness Lifestyle pillars including sleep and recovery, cycle aligned movement and nourishment, cellular health and some other health optimisation practices that actually nourish you. A softer, more sustainable approach to wellness – focused on connection and community But the masterclass is just the beginning. Estee offers a range of transformational services to support individuals at every stage of their wellness journey. Her practice is built around two other core offerings: Somatic Work Personalized support through 1:1 sessions online or in-person sessions, where clients are guided through TRE (Tension, Stress & Trauma Release Exercise) – a body-based practice to release stored stress and reset the nervous system. Ideal for those needing deeper emotional and physical grounding. The Path: 6-Month Transformational Program Estee's signature, high-touch program that includes personalized biological age testing (in partnership with GlycanAge), customized plans, holistic protocols, and continuous coaching. It's an intimate experience built around accountability, deep change, and long-term vitality. Why It Matters Today, many people assume they are living healthy lives – but when they take a biological age test, they're shocked to discover their body is aging faster than expected. Estee's mission is to close this gap through a gentle, scientific, and highly personalised approach. The masterclass not only educates but empowers people to take back control of their health & longevity. The Refined Masterclass is now live. To learn more and join the experience, visit Estee's website or follow her on Instagram
CNN
an hour ago
- CNN
Ukrainian boxer to Trump: ‘Open your eyes'
Ukrainian boxer to Trump: 'Open your eyes' World heavyweight boxing champion Oleksandr Usyk shared a message for President Trump in an interview with CNN, asking him to help Ukraine as it continues its fight against a full-scale Russian invasion. 00:54 - Source: CNN Why China doesn't need the US auto market If there is one thing to be learned from Auto Shanghai - China's largest automobile show - it's that China has dozens of car brands that can rival Western ones. BYD surpassed Tesla's profits, but other EVs like those made by Zeekr, Xiaomi and Chery are quickly joining the race. CNN's Marc Stewart took a rare test drive of Zeekr's new 7GT. 00:44 - Source: CNN Analysis: Trump is in a crisis of his own making Trump tells President Vladimir Putin to stop after Russia launched its deadliest wave of attacks on Kyiv in nine months. This comes days after Trump said the US would walk out on efforts to make a peace deal in Ukraine if it didn't see progress. CNN's Nick Paton Walsh breaks down the latest. 01:03 - Source: CNN Russia launches strikes across Ukraine Russia launched waves of drones and ballistic missiles at multiple targets across a broad swath of Ukraine overnight killing at least four people in the capital Kyiv and wounding around 40 across the country. 00:32 - Source: CNN German leader on 'terrible' impact of Trump's tariffs In an interview with CNN's Jake Tapper, German Chancellor Friedrich Merz talks about the impact President Trump's tariffs are having on the auto industry. 01:13 - Source: CNN Greta Thunberg sails to Gaza Greta Thunberg has set sail with eleven other activists to Gaza. The activist group they're part of, The Freedom Flotilla Coalition, is attempting to bring aid and raise international awareness over the ongoing humanitarian crisis in the territory. 00:59 - Source: CNN Record rain floods Mexico City, traps people Mexico City was hit with record rainfall that didn't relent for more than five hours Monday night, marking the heaviest rain since 2017, according to water management officials. CNN's Valeria León walks a flooded avenue of the nation's capital after emergency crews worked through the night to rescue several trapped drivers. 00:43 - Source: CNN Gaza aid distribution turns deadly for third consecutive day For a third consecutive day, Palestinians came under fire while trying to receive aid from a distribution site in Gaza. According to the Palestinian Ministry of Health and Nasser hospital, at least 27 people were killed and dozens injured on June 3. 00:56 - Source: CNN Analysis: Why Ukraine's drone attack on Russia just changed the world CNN's Jim Sciutto explains why Ukraine's large-scale drone attack on Russian air bases thousands of miles behind the front lines struck fear into the heart of every global superpower 01:05 - Source: CNN Tomatoes fly at Colombia's largest food fight Around 20,000 revellers gathered in Sutamarchán, Colombia, to throw over 45 tonnes of tomatoes at each other. The Gran Tomatina festival, now in its 15th year, is hosted to celebrate the economy of Sutamarchán, which is centred around tomato production. Mayor Miguel Andrés Rodríguez said "between 70 and 80 percent of families [in Sutamarchán] live off tomatoes. This is a tribute to them." The festival uses tomatoes which are overripe, or otherwise not suitable for consumption. 00:30 - Source: CNN Palestinians shot dead near Gaza aid hub The Palestinian health ministry, hospital officials and multiple eyewitnesses say deadly gunfire killed dozens of Palestinians near an aid distribution site in Gaza on Sunday, with Israel's military denying that its troops fired 'within or near' the aid site. CNN Jerusalem correspondent Jeremy Diamond brings you up to speed on what we know about the weekend chaos. 02:31 - Source: CNN Palestinians describe deadly shooting near aid center in Gaza CNN spoke to multiple witnesses who recounted the deadly chaos that unfolded near a US-backed aid center in southern Gaza after more than 30 Palestinians were killed and dozens injured on Sunday, according to the Palestinian Ministry of Health. The health ministry blamed the Israeli military for the deaths while other witnesses claimed that local security personnel had also opened fire. Gaza Humanitarian Foundation, which runs the aid center, said there had been no gunfire at the site and Israel Defense Forces denied firing on civilians at or close to the site, calling such accusations 'false reports.' 00:55 - Source: CNN Palestinian UN envoy breaks down talking about Gaza's children The Palestinian ambassador to the UN made an emotional address, saying more than 1,300 children have been killed in Gaza since Israel ended the ceasefire in March. 01:19 - Source: CNN Political candidate wears body armor daily CNN's David Culver met César Gutiérrez Priego as he was readying to campaign for office in Mexico City. Gutiérrez Priego, who is running for a seat on the Supreme Court in Mexico, shows Culver the safety precautions he takes with political violence in Mexico at an all-time high. See Culver's full reporting on CNN. 00:53 - Source: CNN Harvard students and faculty speak out against Trump Harvard students and faculty spoke to CNN ahead of commencement as Donald Trump said the university should cap foreign enrollment. The Trump administration has recently sought to cancel $100 million in contracts with the school. 02:03 - Source: CNN Palestinians desperate for food rush US-backed aid site Scores of people rushed over fencing and through barricades in southern Gaza on the first day a US-Israeli-backed aid site was opened. CNN's Jeremy Diamond explains the desperate humanitarian situation that remains in the region. 01:22 - Source: CNN Journalists spit on at Jerusalem Day flag march Ultra-nationalist Israeli Jews chanted anti-Arab slogans as they marched through Jerusalem's Old City to mark Jerusalem Day. CNN's Oren Liebermann describes heavy police presence on the ground. Members of the crowd were seen spitting on journalists, including a CNN producer. 01:50 - Source: CNN Finland's president responds to Russian military activity along border CNN's Erin Burnett speaks with Finland's President Alexander Stubb about his country ramping up its military to deter potential Russian aggression. 02:16 - Source: CNN King Charles stresses Canada's 'self determination' amid pressure from US King Charles III delivered the ceremonial Speech from the Throne in the Canadian Senate. The address marks only the second time in Canadian history that the reigning sovereign has opened parliament, and the third time that the British monarch has delivered the address. 00:42 - Source: CNN Huge ship refloated after nearly crashing into house A larger container ship has been refloated after nearly crashing into a house in Norway. According to local police, the navigator had fallen asleep at the helm. 00:42 - Source: CNN Vehicle plows into crowd in Liverpool Police in the United Kingdom say a man has been arrested after a car plowed into Liverpool fans celebrating during the soccer club's Premier League trophy parade. 01:14 - Source: CNN
Medscape
an hour ago
- Medscape
Worm-Inspired Treatments Inch Toward the Clinic
The experiment was a striking attempt to investigate weight control. For 6 weeks, a group of mice gorged on lard-enriched mouse chow, then scientists infected the mice with worms. The worms wriggled beneath the animals' skin, migrated to blood vessels that surround the intestines, and started laying eggs. Bruno Guigas, a molecular biologist at the Leiden University Center for Infectious Diseases in the Netherlands, led this study some years back and the results, he says, were 'quite spectacular.' The mice lost fat and gained less weight overall than mice not exposed to worms. Within a month or so, he recalls, the scientists barely needed their scale to see that the worm-infested mice were leaner than their worm-free counterparts. Infection with worms, it seems, reversed obesity, the researchers reported in 2015. While it's true that worms gobble up food their hosts might otherwise digest, that doesn't seem to be the only mechanism at work here. There's also some intricate biology within the emerging scientific field of immunometabolism. Over the past couple of decades, researchers have recognized that the immune system doesn't just fight infection. It's also intertwined with organs like the liver, the pancreas and fat tissue, and implicated in the progression of obesity and type 2 diabetes. These and other metabolic disorders generate a troublesome immune response — inflammation — that worsens metabolism still further. Metabolic disease, in other words, is inflammatory disease. Scientists have also observed a metabolic influence of worms in people who became naturally infected with the parasites or were purposely seeded with worms in clinical trials. While the physiology isn't fully understood, the worms seem to dampen inflammation, as discussed in the 2024 Annual Review of Nutrition . 'We're never going to cure or treat metabolic disease with worm infections,' says Guigas. They cause unpleasant side effects like nausea, and it would be impractical to dose millions of people with parasites. But worms can be valuable tools for scientists to understand the feedback between inflammation and metabolism. The findings could inspire more traditional, less ick-inducing treatments. The Worms' Good Turns The worms we're talking about are helminths such as flukes and roundworms. While they've largely been eliminated from developed nations, an estimated 1.5 billion people worldwide carry them. They can be dangerous in high numbers, and cause symptoms such as diarrhea and malnutrition in those at high risk, including children and immunocompromised individuals, and during pregnancy. But for most people, infection with a few worms is pretty benign. 'Throughout human evolution, I think, there's been this nice sort of truce,' says Paul Giacomin, an immunologist at James Cook University in Cairns, Australia. As part of that detente, he says, helminths evolved molecules that tell the human immune system, 'I'm not here, don't worry about me.' In turn, people might have evolved to depend a bit on worms to temper inflammation. Today, metabolic disease is a massive global problem, with obesity affecting an estimated 890 million people. Another 580 million have type 2 diabetes, which arises when the hormone insulin, which controls blood sugar levels, is in short supply or the body's cells become insensitive to it. Links between metabolic disease and worm infection emerged from research on human populations. Studies in Australia, Turkey, Brazil, China, India and Indonesia showed that people with metabolic conditions such as diabetes were less likely to have helminth infections, and vice versa. 'This observation is quite strong,' says Ari Molofsky, an immunologist at the University of California, San Francisco. Going a step further, scientists observed what happened when they provided deworming treatments.' The overwhelming majority of the studies showed that deworming worsens your metabolic health,' says Giacomin. Scientists looked to lab mice for additional clues. Molofsky and colleagues, in 2011, reported that when they infected mice on high-fat food with the gut worm Nippostrongylus brasiliensis , the infection improved blood sugar control. Similarly, in Guigas' study, published in 2015, the worms — blood flukes called Schistosoma mansoni — improved not just weight, but also blood sugar processing. And the worms needn't be alive: Even molecules collected from crushed worm eggs improved metabolism. The going hypothesis is that metabolic problems kick off a vicious immunometabolic cycle. First, Guigas says, damaged cells in metabolic organs cry for help, releasing molecular signals that call in immune cells. When the immune cells arrive, they morph into forms that promote a type of inflammation called Th1. Th1 responses are good at combating viruses, but they're the wrong choice here. Th1 can aggravate metabolic problems by impairing insulin manufacture, altering insulin signaling and amplifying insulin resistance. Thus, instead of helping, the immune cells cause further stress in the metabolic tissues. So the tissues call in more immune cells — and the cycle repeats. Worms seem to break the cycle. In great part, that's probably because their 'I'm not here' message causes a different kind of immune response, Th2, that dampens the Th1 reaction and re-normalizes the system. Other mechanisms might also be at work: Worms might reduce appetite; it's known they can alter gut microbes; and Guigas suspects they can also manipulate creatures' metabolisms via non-immune pathways. 'The parasitic worms are real masters at controlling inflammation,' says Giacomin, who coauthored an article on helminths and immunity in the 2021 Annual Review of Immunology . Thus, scientists interested in controlling immunometabolic disease might take cues from these wriggly little metabolic masterminds. In fact, researchers have already tested helminths to control inflammation in autoimmune conditions such as inflammatory bowel disease. The accumulating evidence linking worms to metabolic benefits in animals and people inspired Giacomin and colleagues to conduct a trial of their own. Commencing in 2018, they decided to try the hookworm Necator americanus in 27 obese people who had insulin resistance, putting them at risk for type 2 diabetes. The researchers applied worm larvae in patches on the subjects' arms; after passing through the skin, the worms would travel through the blood stream, to the lungs and then to the small intestine. An additional 13 participants were assigned to placebo patches with Tabasco sauce to mimic the itch of entering worms. N americanus is a common cause of hookworm infections across much of the world. While most cases are asymptomatic, the time when the worms are attaching to the intestinal wall can cause symptoms like nausea and low iron levels, especially if there are a lot of worms. So the main goal was to determine if the treatment was safe, trying doses of 20 or 40 worms. Many subjects suffered short-term unpleasantness such as bloating or diarrhea as they adjusted to their new intestinal tagalongs, but overall, most did fine. After 12 months, the people who got hookworms had lower insulin resistance and reduced fasting blood sugar levels. After two years, those who received 20 worms had lost an average of 11 pounds — though not all individuals lost weight, and some gained. 'It was quite convincing that the worms were having some sort of beneficial effect,' says Giacomin. The subjects were convinced too: When the study was over, the researchers offered deworming, but most participants elected to keep their worms. Giacomin and Guigas hope to identify worm components or invent worm-inspired molecules to produce similar effects without whole parasites. Giacomin cofounded a company, Macrobiome Therapeutics in Cairns, to develop hookworm molecules into treatments. Such medications might be based on the wriggly parasites, but they'd be an easier pill to swallow.
